Polypeptide inhibitor modified with polyethylene glycol for inhibiting vascular endothelial growth factor receptors 2 tyrosine kinase and application thereof.
A growth factor receptor and tyrosine kinase technology, applied in the direction of peptides, anti-inflammatory agents, non-central analgesics, etc., to achieve less side effects, significant rheumatoid arthritis, and polyethylene glycol-modified vascular endothelial growth Effects of Science on Factor Receptor 2 Tyrosine Kinase Peptide Inhibitors
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0017] Immunoprotective effect of polyethylene glycol-modified vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor in collagen-induced mouse arthritis animal model
[0018] To construct collagen-type mouse arthritis animal model, and to study the therapeutic effect of polyethylene glycol-modified vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely normal control group, model control group, peptide inhibitor 1 low, middle and high dosage groups (5, 10 , 20 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group o...
Embodiment 2
[0023] In vivo immunoprotective effect of polyethylene glycol-modified vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor on adjuvanted rat arthritis animal model
[0024]To construct an adjuvant rat arthritis animal model, and to study the therapeutic effect of polyethylene glycol-modified vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, weighing 140 g-160 g, were randomly divided into 6 groups, which were normal control group, model control group, polyethylene glycol-modified vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor low There were 3 medium and high dose groups (5, 10, 20 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the norma...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com